NEWS RELEASE

Participation of Interprotein in the space experiment for generation of high-quality protein crystals in "Kibo"

March 20, 2014 – Interprotein Corporation (Interprotein) today announced that Interprotein will participate in the first experiment of the second series for generation of high-quality protein crystals in the Japanese Experiment Module "Kibo" on the International Space Station (ISS) as one of the nongovernmental enterprises.

The present experiment will be conducted by Japan Aerospace Exploration Agency (JAXA) and Interprotein also will submit protein samples for the space experiment*. Koichi Wakata will support the first experiment. In this experiment, Interprotein is aiming at the acquisition of co-crystal consisting of protein and small molecule. We expect that design and synthesis compounds would be promoted more efficiently based on the minute information about compound binding pose brought by high-quality co-crystal that would be generated under the microgravity environment of Kibo.

Interprotein would actively utilize such opportunities hereafter since JAXA has the world's most advanced technologies and know-hows to obtain high-quality protein crystals in space and is providing opportunities for nongovernmental enterprises to participate in the space experiments.

***About the space experiment (the first experiment for the second series)**

Launch date:	March 26, 2014
Launch site:	Baikonur Cosmodrome in Kazakhstan
Scheduled return date:	May 14, 2014
Landing location:	Kazakhstan
Return flight:	By Soyuz Spacecraft

About Interprotein:

Interprotein is conducting research and development of small molecule medicines based on unique *in silico* molecular design strategy, INTENDD (INTerprotein's Engine for New Drug Design) and peptide medicines based on helix-loop-helix type conformationally-constrained peptide (MicroAntibody) technology. These platform technologies are applicable to drug discovery researches of not only protein-protein interaction inhibitors (PPIs) but also non-PPIs. In addition, MicroAntibody technology exercises its power over especially the case that the target molecule recognizes α-helix structure, but is also applicable to the case that the target molecule does not recognize α-helix structure or the X-ray crystal structure has not been clarified.

Japan Aerospace Exploration Agency

Pharmaceutical Companies Participation in High-Quality Protein Crystal Growth Experiment on Kibo
http://www.jaxa.jp/press/2014/03/20140320_protein_e.html

Contact:

Interprotein Corporation
R&D and BD Division
Hirotsugu KOMATSU, Ph.D.
TEL: +81-(0)42-770-9477
FAX: +81-(0)42-770-9477
E-mail: info@interprotein.com